5-MeO-DMT Research and Clinical Trials

Research has progressed beyond surveys and case reports, but the evidence base is still small. One peer-reviewed randomized trial has produced promising short-term findings in treatment-resistant depression. Other completed studies are primarily small, open-label or early safety studies. More independent research with larger and more diverse populations is needed.

Researchers are evaluating standardized synthetic formulations of 5-MeO-DMT, also called mebufotenin. GH001 is an inhaled formulation, while BPL-003 is administered intranasally in clinical studies. Research has focused mainly on treatment-resistant depression, with smaller preliminary studies involving postpartum depression and alcohol use disorder.

The strongest clinical evidence comes from a phase 2b trial involving 81 adults with treatment-resistant depression at 16 European research sites. Forty participants received GH001 and 41 received placebo. The randomized, placebo-controlled comparison lasted seven days, followed by a six-month open-label extension.

At day 8, the GH001 group had a 15.5-point greater reduction on a clinician-rated depression scale than the placebo group. Remission was recorded in 57.5% of the GH001 group and none of the placebo group. In this trial, remission meant reaching a specified rating-scale score. It did not mean that depression was permanently cured.

The controlled comparison lasted only seven days and involved a modest, highly screened sample. All participants were recorded as White, limiting conclusions about broader populations. The noticeable psychoactive effects may also have revealed treatment assignment to some participants. The study was funded by the developer, and company personnel participated in the research.

Longer-term findings came from an open-label extension without a placebo comparison. Twenty of the 23 participants who initially reached remission later received another treatment, with a median time of approximately six weeks. This does not erase the short-term result, but it shows why one treatment should not be described as a permanent cure.

A placebo-controlled phase 1 study evaluated intranasal BPL-003 in 44 healthy participants. It primarily measured short-term safety, tolerability and how the compound moved through the body. It was not designed to establish effectiveness for depression or another condition.

A postpartum-depression study enrolled 10 participants and had no control group. An alcohol-use-disorder study enrolled 13 participants and combined BPL-003 with preparation, integration and cognitive behavioral therapy. These studies may guide future research, but their small size and lack of control groups prevent firm conclusions about treatment effectiveness.

Earlier surveys reported that some people perceived improvements in depression or anxiety after 5-MeO-DMT use. These studies relied on voluntary, retrospective reports and did not include randomized control groups. They can identify patterns worth investigating, but they cannot prove that 5-MeO-DMT caused an improvement.

During the controlled week of the GH001 trial, adverse events occurred more often with GH001 than placebo. All reported events were mild or moderate, and no serious adverse events or discontinuations occurred during that period. Nausea was the most common event. A short trial cannot establish rare risks, long-term safety or safety in people excluded from clinical studies.

For contraindications, medication concerns and emergency information, read 5-MeO-DMT Safety, Risks and Medication Interactions.

Clinical studies use standardized synthetic formulations, defined eligibility criteria, medical screening, trained research teams, monitoring and predetermined outcome measures. These findings cannot be assumed to apply to toad secretion, informal administration, ceremonies or retreats. Composition, setting, participant selection and emergency resources may differ substantially.

No 5-MeO-DMT product is currently FDA-approved to treat depression or any other condition. Permission to conduct a clinical trial, removal of a clinical hold or a special development designation does not mean a product has been approved. FDA approval requires an evaluation of evidence submitted for a specific product and intended use.